|

|

| U.S. Nuclear
Power Reactor Map
iOSAT™
received its approval from the US Food and Drug Administration in 1982,
and is the only full-strength tablet for radiation blocking which may
legally be sold in the US. Only iOSAT™ has passed all FDA tests for purity, quality, safety and efficacy.
Meets all FDA requirements
for potassium iodide as a radiation protective, and is labeled and packaged
in accordance with US government guidelines.
Has demonstrated all quality controls and passed all FDA requirements
for purity, quality, safety, efficacy.
Comes full strength (130
mg of potassium iodide per tablet) in accordance with FDA demands for complete
thyroid blocking.
|
|
|
|
|
iOSAT™
FDA
APPROVED POTASSIUM IODIDE THYROID BLOCKING TABLETS

FOR
USE IN A RADIATION EMERGENCY
Radioactive Iodine is a byproduct of nuclear fission processes in
nuclear reactors and nuclear weapons. You can protect yourself from
the effects of cancer-causing radioactive iodine with FDA Approved
IOSAT™ Potassium Iodide (KI). A non-prescription drug,
Potassium Iodide protects against radioactive iodine by preventing
its absorption
by the thyroid gland located in the neck. The U.S. government
has a limited supply in case of a nuclear bomb detonation or nuclear reactor accident/attack, yet Potassium
Iodide must be taken during or before exposure to radioactive iodine
to be effective.


|

|
|

|

| U.S. Power Reactor
Radiation Zones
Contains no potassium iodate
or other adulterants. Contains only pure potassium iodide as the active
ingredient.
IOSAT [potassium iodide]
Is manufactured in the United States under strict FDA GMP guidelines,
and
holds an approved New Drug Application (NDA).
IOSAT [potassium iodide]
Was the first product of its kind (since 1982) and is the only product that
can be purchased by local, state and federal governments.
Is widely purchased by nuclear utilities.
IOSAT [potassium iodide]
offers unit dose packaging for maximum shelf-life and allows for individual
tablet distribution without fear of loss of packaging integrity.
|
|
|